文献速递真菌感染

血浆微生物游离DNA测序诊断高危免疫抑制患者侵袭性真菌病

Plasma Microbial Cell-free DNA Metagenomic Sequencing for Diagnosis of Invasive Fungal Diseases Among High-risk Outpatient and Inpatient Immunocompromised Hosts.
PubMed 文献 · Clin Infect Dis · 2025-01-01

本病例对照研究利用前瞻性收集的存档血浆标本,评估微生物游离DNA(mcfDNA)测序在高危免疫抑制宿主中诊断侵袭性真菌病(IFD)的性能,以2008年MSG/EORTC标准为金标准。65例确诊或临床诊断IFD患者与65例无IFD对照中,总体敏感性47.7%、特异性100%;敏感性在确诊IFD高于临床诊断IFD(60.0% vs 37.1%),侵袭性毛霉病高于曲霉病(100% vs 45.7%)。

要点

  • mcfDNA测序诊断IFD总体敏感性47.7%,特异性100%。
  • 确诊IFD敏感性60.0%,高于临床诊断IFD的37.1%。
  • 侵袭性毛霉病敏感性100%,高于曲霉病的45.7%。

核心结论

  • mcfDNA测序阳性结果可能减少疑似IFD患者的侵入性采样需求。
  • 该探索性分析中,mcfDNA测序对侵袭性毛霉病的高敏感性提示其可能有助于该IFD的早期治疗和干预。
  • 未来研究应关注特定因素如何影响mcfDNA测序对侵袭性曲霉病的敏感性。

研究设计与样本

  • 病例对照研究,使用前瞻性收集的存档血浆标本和Aspergillus Technology Consortium Repository数据。
  • 研究对象为高危免疫抑制宿主,包括血液恶性肿瘤、干细胞移植和实体器官移植患者。
  • 以2008年Mycoses Study Group/European Organization for the Research and Treatment of Cancer诊断标准为金标准。
  • 纳入65例确诊或临床诊断IFD成人受试者和65例无IFD对照。

主要发现

  • IFD episodes中曲霉最常见(70.8%,46/65),其次为毛霉目(10.8%,7/65)。
  • 总体敏感性47.7%,特异性100%。
  • 确诊IFD敏感性60.0%,临床诊断IFD敏感性37.1%。
  • 侵袭性毛霉病敏感性100%,侵袭性曲霉病敏感性45.7%。

临床怎么用

  • mcfDNA测序阳性结果可能减少疑似IFD患者的侵入性采样需求。
  • 对侵袭性毛霉病的高敏感性提示其可能有助于早期治疗和干预。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: New and minimally invasive tools to aid the diagnosis of invasive fungal diseases (IFD) are urgently needed as the immunocompromised population at highest risk increases. Advancements in molecular technology have rendered new diagnostics more readily available for clinical use. METHODS: This case-control study used prospectively collected archived plasma specimens and data from the Aspergillus Technology Consortium Repository to investigate the diagnostic performance of microbial cell-free DNA (mcfDNA) sequencing as a minimally invasive diagnostic for IFDs in a population of high-risk immunocompromised hosts including hematologic malignancy, stem cell, and solid organ transplants patients. The 2008 Mycoses Study Group/European Organization for the Research and Treatment of Cancer diagnostic criteria served as the gold standard for test performance. RESULTS: Sixty-five adult subjects with proven or probable IFD and 65 controls without IFD were included. Among IFD episodes Aspergillus was the most common pathogen (70.8%, 46/65), followed by Mucorales (10.8%, 7/65). Overall, sensitivity was 47.7% and specificity was 100%. Sensitivity varied based on disease certainty and pathogen; sensitivity was higher in proven versus probable IFD (60.0% vs 37.1%, respectively) and higher for subjects with invasive mucormycosis (100%) compared with aspergillosis (45.7%). CONCLUSIONS: A positive result by mcfDNA sequencing may reduce the need for invasive sampling in patients with suspected IFD. In this exploratory analysis, its high sensitivity and specificity for invasive mucormycosis suggests it could be useful for early treatment and intervention of this IFD. Future studies should focus on understanding how specific factors impact the sensitivity of mcfDNA sequencing for invasive aspergillosis.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Sim BZ, Mah JK, Heldman MR, et al. Plasma Microbial Cell-free DNA Metagenomic Sequencing for Diagnosis of Invasive Fungal Diseases Among High-risk Outpatient and Inpatient Immunocompromised Hosts. Clin Infect Dis. 2025. PMID: 40176261. doi:10.1093/cid/ciaf170

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。